EsoCap AG has received Orphan Drug Designation from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE (eosinophilic esophagitis).
“We are pleased that the FDA has recognized ESO-101’s potential to offer a significant therapeutic benefit for patients suffering from EoE”, said Isabelle Racamier, EsoCap AG CEO, “We believe that EsoCap’s highly promising and innovative technology will represent a major advance for this rare condition”.
